Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines

Clinical and Vaccine Immunology

Volumn 14, Issue 6, 2007, Pages 792-795

  Garland, Suzanne M ^a,b   Steben, Marc ^c   Hernandez Avila, Mauricio ^d   Koutsky, Laura A ^e   Wheeler, Cosette M ^f   Perez, Gonzalo ^g   Harper, Diane M ^h   Leodolter, Sepp ⁱ   Tang, Grace W K ^j   Ferris, Daron G ^k   Esser, Mark T ^l   Vuocolo, Scott C ^l   Nelson, Micki ^l   Railkar, Radha ^l   Sattler, Carlos ^l   Barr, Eliav ^l  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c INSTITUT NATIONAL DE SANTÉ PUBLIQUE DU QUÉBEC   (Canada)

^d INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^g National Research Center   (Colombia)

^h DARTMOUTH MEDICAL SCHOOL   (United States)

ⁱ MEDICAL UNIVERSITY OF VIENNA   (Austria)

^j UNIVERSITY OF HONG KONG   (Hong Kong)

^k MEDICAL COLLEGE OF GEORGIA   (United States)

^l MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MONOVALENT HUMAN PAPILLOMA VIRUS TYPE 16 VACCINE; PLACEBO; QUADRIVALENT HUMAN PAPILLOMA VIRUS TYPE 16 VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INFECTION; VIRUS LIKE AGENT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; DOUBLE-BLIND METHOD; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 34547109354     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00478-06     Document Type: Article

References (10)

1. Cates, W., Jr. 1999. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. Sex. Transm. Dis. 26(4 Suppl.):S2-S7.
2. Dias, D., J. Van Doren, S. Schlottmann, S. Kelly, D. Puchalski, W. Ruiz, P. Boerckel, J. Kessler, J. M. Antonello, T. Green, M. Brown, J. Smith, N. Chirmule, E. Barr, K. U. Jansen, and M. T. Esser. 2005. Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin. Diagn. Lab. Immunol. 12:959-969.
3. Edwards, K. M., and M. D. Decker. 1997. Combination vaccines consisting of acellular pertussis vaccines. Pediatr. Infect. Dis. J. 16(4 Suppl.):S97-S102.
4. Garland, S. M., M. Hernandez-Avila, C. M. Wheeler, G. Perez, D. M. Harper, S. Leodolter, G. W. K. Tang, D. G. Ferris, M. Steben, J. T. Bryan, F. J. Taddeo, R. Railkar, M. T. Esser, H. L. Sings, M. Nelson, J. Boslego, C. Sattler, E. Barr, and L. A. Kowtsky. Quadrivalent vaccine against human papillomavirus to prevent anogenital disease. N. Engl. J. Med., in press.
5. Miettinen, O., and M. Nurminen. 1985. Comparative analysis of two rates. Stat. Med. 4:213-226.
6. Muñoz, N., F. X. Bosch, S. de Sanjosé, R. Herrero, X. Castellsagué, K. V. Shah, P. J. F. Snijders, C. J. L. M. Meijer, et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348:518-527.
7. Stanberry, L. R., S. L. Spruance, A. L. Cunningham, D. I. Bernstein, A. Mindel, S. Sacks, S. Tyring, F. Y. Aoki, M. Slaoui, M. Denis, P. Vandepapeliere, G. Dubin, et al. 2002. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347:1652-1661.
8. Trollfors, B., J. Taranger, T. Lagergard, and V. Sundh. 2005. Reduced immunogenicity of diphtheria and tetanus toxoids when combined with pertussis toxoid. Pediatr. Infect. Dis. J. 24:85-86.
9. Villa, L. L., R. L. R. Costa, C. A. Petta, R. P. Andrade, K. A. Ault, A. R. Giuliano, C. M. Wheeler, L. A. Koutsky, C. Malm, M. Lehtinen, F. E. Skjeldestad, S. E. Olsson, M. Steinvall, D. R. Brown, R. J. Kurman, B. M. Ronnett, M. H. Stoler, A. Ferenczy, D. M. Harper, G. M. Tamms, J. Yu, L. Lupinacci, R. Railkar, F. J. Taddeo, K. U. Jansen, M. T. Esser, H. L. Sings, A. J. Saah, and E. Barr. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 6:271-278.
10. Walboomers, J. M. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, A. Kummer, K. V. Shah, and P. J. F. Snijders. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.